TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Cocco, E; Lee, JE; Kannan, S; Schram, AM; Won, HH; Shifman, S; Kulick, A; Baldino, L; Toska, E; Arruabarrena-Aristorena, A; Kittane, S; Wu, F; Cai, YY; Arena, S; Mussolin, B; Kannan, R; Vasan, N; Gorelick, AN; Berger, MF; Novoplansky, O; Jagadeeshan, S; Liao, Y; Rix, U; Misale, S; Taylor, BS; Bardelli, A; Hechtman, JF; Hyman, DM; Elkabets, M; de Stanchina, E; Verma, CS; Ventura, A; Drilon, A; Scaltriti, M

Cocco, E; Scaltriti, M (corresponding author), Mem Sloan Kettering Canc Ctr, Room Z-1702,1275 York Ave,Box 20, New York, NY 10065 USA.; Verma, CS (corresponding author), ASTAR, Bioinformat Inst, 30 Biopolis St,07-01 Matrix, Singapore 138671, Singapore.; Ventura, A (corresponding author), Mem Sloan Kettering Canc Ctr, Zuckerman Res Lab, 417 East 68th St, New York, NY 10065 USA.; Drilon, A (corresponding author), Mem Sloan Kettering Canc Ctr, 885 Second Ave, New York, NY 10017 USA.

CANCER DISCOVERY, 2021; 11 (1): 126